Literature DB >> 8925658

Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren's syndrome.

I Toda1, N Shinozaki, K Tsubota.   

Abstract

Our purpose was to evaluate the efficacy of a new formulation of methylcellulose, preservative-free 0.5% hydroxypropyl methylcellulose (HPMC), for the treatment of dry eye. In the clinical part of our study, two groups of dry-eye patients, those with Sjögren's syndrome (SS) and those without (non-SS), were treated topically with 0.5% HPMC and evaluated for symptoms, ocular surface vital staining, tear breakup time (BUT), and tear evaporation rate from the ocular surface at 40% ambient humidity (TEROS40). In the in vivo part of the study, rose bengal uptake was measured in human conjunctival epithelial cells, which were cultured and incubated with or without 0.5% HPMC. Although symptoms improved in both groups, rose bengal and fluorescein staining and BUT improved significantly only in the SS group. TEROS40 increased for 30 min after instillation of 0.5% HPMC, but not after use of 0.1% sodium hyaluronate or saline-based artificial tears. Rose bengal uptake by cultured conjunctival epithelial cells was blocked by 0.5% HPMC. These findings suggest that 0.5% HPMC provides long coverage of and protection for the ocular surface. Patients with severe dry eye, such as in SS, are good candidates for this treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8925658     DOI: 10.1097/00003226-199603000-00003

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  16 in total

Review 1.  Topical and systemic medications for the treatment of primary Sjögren's syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Antoni Sisó-Almirall; Xavier Bosch; Athanasios G Tzioufas
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

2.  Cytoprotective effect of hyaluronic acid and hydroxypropyl methylcellulose against DNA damage induced by thimerosal in Chang conjunctival cells.

Authors:  Juan Ye; Huina Zhang; Han Wu; Changjun Wang; Xin Shi; Jiajun Xie; Jinjing He; Jun Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-06-24       Impact factor: 3.117

3.  Hydroxy-propyl-methyl-cellulose is a safe and effective lifting agent for endoscopic mucosal resection of large colorectal polyps.

Authors:  A Arezzo; N Pagano; F Romeo; G Delconte; C Hervoso; M Morino; A Repici
Journal:  Surg Endosc       Date:  2008-10-02       Impact factor: 4.584

Review 4.  Sjögren syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  CMAJ       Date:  2014-02-24       Impact factor: 8.262

Review 5.  Treatment of primary Sjögren syndrome.

Authors:  Alain Saraux; Jacques-Olivier Pers; Valérie Devauchelle-Pensec
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

6.  Dry eye after haematopoietic stem cell transplantation.

Authors:  Y Ogawa; S Okamoto; M Wakui; R Watanabe; M Yamada; M Yoshino; M Ono; H Y Yang; Y Mashima; Y Oguchi; Y Ikeda; K Tsubota
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

7.  [Toxicity of a new moistening agent and preservative in vitro].

Authors:  K Kasper; C Kremling; G Geerling
Journal:  Ophthalmologe       Date:  2008-06       Impact factor: 1.059

Review 8.  An overview on dry eye treatment: approaches for cyclosporin a delivery.

Authors:  Burçin Yavuz; Sibel Bozdağ Pehlivan; Nurşen Unlü
Journal:  ScientificWorldJournal       Date:  2012-04-24

9.  Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study.

Authors:  Pinnita Prabhasawat; Ngamkae Ruangvaravate; Nattaporn Tesavibul; Maneerat Thewthong
Journal:  J Ocul Pharmacol Ther       Date:  2015-06-19       Impact factor: 2.671

10.  Preparation and characterisation of fluconazole vaginal films for the treatment of vaginal candidiasis.

Authors:  L Kumar; M S Reddy; R K Shirodkar; G K Pai; V T Krishna; R Verma
Journal:  Indian J Pharm Sci       Date:  2013-09       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.